172 related articles for article (PubMed ID: 22283742)
1. Update on the use of defibrotide.
Guglielmelli T; Bringhen S; Palumbo A
Expert Opin Biol Ther; 2012 Mar; 12(3):353-61. PubMed ID: 22283742
[TBL] [Abstract][Full Text] [Related]
2. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies.
Ho VT; Revta C; Richardson PG
Bone Marrow Transplant; 2008 Feb; 41(3):229-37. PubMed ID: 17994121
[TBL] [Abstract][Full Text] [Related]
3. Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children.
Qureshi A; Marshall L; Lancaster D
Pediatr Blood Cancer; 2008 Apr; 50(4):831-2. PubMed ID: 18286502
[TBL] [Abstract][Full Text] [Related]
4. Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation.
Corbacioglu S; Richardson PG
Expert Rev Gastroenterol Hepatol; 2017 Oct; 11(10):885-898. PubMed ID: 28825848
[TBL] [Abstract][Full Text] [Related]
5. Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.
Corbacioglu S; Kernan N; Lehmann L; Brochstein J; Revta C; Grupp S; Martin P; Richardson PG
Expert Rev Hematol; 2012 Jun; 5(3):291-302. PubMed ID: 22780209
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment with defibrotide for sinusoidal obstruction syndrome after hematopoietic stem cell transplantation.
Yakushijin K; Matsui T; Okamura A; Yamamoto K; Ito M; Chihara K
Kobe J Med Sci; 2005; 51(3-4):55-65. PubMed ID: 16444097
[TBL] [Abstract][Full Text] [Related]
7. The use of defibrotide in blood and marrow transplantation.
Richardson PG; Carreras E; Iacobelli M; Nejadnik B
Blood Adv; 2018 Jun; 2(12):1495-1509. PubMed ID: 29945939
[TBL] [Abstract][Full Text] [Related]
8. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial.
Corbacioglu S; Cesaro S; Faraci M; Valteau-Couanet D; Gruhn B; Rovelli A; Boelens JJ; Hewitt A; Schrum J; Schulz AS; Müller I; Stein J; Wynn R; Greil J; Sykora KW; Matthes-Martin S; Führer M; O'Meara A; Toporski J; Sedlacek P; Schlegel PG; Ehlert K; Fasth A; Winiarski J; Arvidson J; Mauz-Körholz C; Ozsahin H; Schrauder A; Bader P; Massaro J; D'Agostino R; Hoyle M; Iacobelli M; Debatin KM; Peters C; Dini G
Lancet; 2012 Apr; 379(9823):1301-9. PubMed ID: 22364685
[TBL] [Abstract][Full Text] [Related]
9. Drug safety evaluation of defibrotide.
Richardson PG; Corbacioglu S; Ho VT; Kernan NA; Lehmann L; Maguire C; Maglio M; Hoyle M; Sardella M; Giralt S; Holler E; Carreras E; Niederwieser D; Soiffer R
Expert Opin Drug Saf; 2013 Jan; 12(1):123-36. PubMed ID: 23228043
[TBL] [Abstract][Full Text] [Related]
10. Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome.
Richardson PG; Triplett BM; Ho VT; Chao N; Dignan FL; Maglio M; Mohty M
Expert Rev Clin Pharmacol; 2018 Feb; 11(2):113-124. PubMed ID: 29301447
[TBL] [Abstract][Full Text] [Related]
11. Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial.
Palumbo A; Larocca A; Genuardi M; Kotwica K; Gay F; Rossi D; Benevolo G; Magarotto V; Cavallo F; Bringhen S; Rus C; Masini L; Iacobelli M; Gaidano G; Mitsiades C; Anderson K; Boccadoro M; Richardson P;
Haematologica; 2010 Jul; 95(7):1144-9. PubMed ID: 20053869
[TBL] [Abstract][Full Text] [Related]
12. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: review and update on the use of defibrotide.
Ho VT; Linden E; Revta C; Richardson PG
Semin Thromb Hemost; 2007 Jun; 33(4):373-88. PubMed ID: 17525895
[TBL] [Abstract][Full Text] [Related]
13. Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias.
Mitsiades CS; Rouleau C; Echart C; Menon K; Teicher B; Distaso M; Palumbo A; Boccadoro M; Anderson KC; Iacobelli M; Richardson PG
Clin Cancer Res; 2009 Feb; 15(4):1210-21. PubMed ID: 19228727
[TBL] [Abstract][Full Text] [Related]
14. Late-onset hepatic veno-occlusive disease post autologous peripheral stem cell transplantation successfully treated with oral defibrotide.
Shah MS; Jeevangi NK; Joshi A; Khattry N
J Cancer Res Ther; 2009; 5(4):312-4. PubMed ID: 20160371
[TBL] [Abstract][Full Text] [Related]
15. Defibrotide blunts the prothrombotic effect of thalidomide on endothelial cells.
Echart CL; Somaini S; Distaso M; Palumbo A; Richardson PG; Fareed J; Iacobelli M
Clin Appl Thromb Hemost; 2012; 18(1):79-86. PubMed ID: 21733935
[TBL] [Abstract][Full Text] [Related]
16. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial.
Richardson PG; Soiffer RJ; Antin JH; Uno H; Jin Z; Kurtzberg J; Martin PL; Steinbach G; Murray KF; Vogelsang GB; Chen AR; Krishnan A; Kernan NA; Avigan DE; Spitzer TR; Shulman HM; Di Salvo DN; Revta C; Warren D; Momtaz P; Bradwin G; Wei LJ; Iacobelli M; McDonald GB; Guinan EC
Biol Blood Marrow Transplant; 2010 Jul; 16(7):1005-17. PubMed ID: 20167278
[TBL] [Abstract][Full Text] [Related]
17. Use of defibrotide in the treatment and prevention of veno-occlusive disease.
Richardson P; Linden E; Revta C; Ho V
Expert Rev Hematol; 2009 Aug; 2(4):365-76. PubMed ID: 21082942
[TBL] [Abstract][Full Text] [Related]
18. Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy.
Haussmann U; Fischer J; Eber S; Scherer F; Seger R; Gungor T
Haematologica; 2006 Jun; 91(6):795-800. PubMed ID: 16769582
[TBL] [Abstract][Full Text] [Related]
19. Defibrotide for the prevention of hepatic veno-occlusive disease after hematopoietic stem cell transplantation: a systematic review.
Zhang L; Wang Y; Huang H
Clin Transplant; 2012; 26(4):511-9. PubMed ID: 22428954
[TBL] [Abstract][Full Text] [Related]
20. Defibrotide, a polydisperse mixture of single-stranded phosphodiester oligonucleotides with lifesaving activity in severe hepatic veno-occlusive disease: clinical outcomes and potential mechanisms of action.
Kornblum N; Ayyanar K; Benimetskaya L; Richardson P; Iacobelli M; Stein CA
Oligonucleotides; 2006; 16(1):105-14. PubMed ID: 16584299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]